Prohibitin expression is associated with high grade breast cancer but is not a driver of amplification at 17q21.33

Webster, Lucy R., Provan, Pamela J., Graham, Dinny J., Byth, Karen, Walker, Robert L., Davis, Sean, Salisbury, Elizabeth L., Morey, Adrienne L., Ward, Robyn L., Hawkins, Nicholas J., Clarke, Christine L., Meltzer, Paul S. and Balleine, Rosemary L. (2013) Prohibitin expression is associated with high grade breast cancer but is not a driver of amplification at 17q21.33. Pathology, 45 7: 629-636. doi:10.1097/PAT.0000000000000004


Author Webster, Lucy R.
Provan, Pamela J.
Graham, Dinny J.
Byth, Karen
Walker, Robert L.
Davis, Sean
Salisbury, Elizabeth L.
Morey, Adrienne L.
Ward, Robyn L.
Hawkins, Nicholas J.
Clarke, Christine L.
Meltzer, Paul S.
Balleine, Rosemary L.
Title Prohibitin expression is associated with high grade breast cancer but is not a driver of amplification at 17q21.33
Journal name Pathology   Check publisher's open access policy
ISSN 0031-3025
1465-3931
Publication date 2013-12
Sub-type Article (original research)
DOI 10.1097/PAT.0000000000000004
Open Access Status Not Open Access
Volume 45
Issue 7
Start page 629
End page 636
Total pages 8
Place of publication Lippincott Williams & Wilkins
Publisher London, United Kingdom
Language eng
Formatted abstract
Aims:  In a study of ductal carcinoma in situ of the breast, we identified five genes at chromosome 17q21.33 that were over-expressed in high grade cases, and showed a correlation between expression and gene copy number. The aim of this study was to investigate potential drivers of genomic amplification at 17q21.33.

Methods:  Analysis of high resolution comparative genomic hybridisation and published data specified a minimum region of amplification at 17q21.33. Prohibitin (PHB) expression was examined by immunohistochemistry in 285 invasive breast cancers. Gene copy number was examined by fluorescence in situ hybridisation.

Results:  The minimum region of amplification at 17q21.33 included ten genes with PHB selected as a candidate driver. Increased PHB expression was associated with higher grade breast cancer and poorer survival. Amplification of PHB was detected in 13 of 235 cases (5.5%) but was not associated with PHB expression. PHB amplification was most common in the ERBB2+ breast cancer subtype, although high expression was most prevalent in basal-like and luminal B cancers. Conclusions: Amplification at 17q21.33 is a recurrent feature of breast cancer that forms part of a 'firestorm' pattern of genomic aberration. PHB is not a driver of amplification, however PHB may contribute to high grade breast cancer.
Keyword Breast cancer
Genomic amplification
Grade
Prohibitin
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Scopus Citation Count Cited 1 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 10 Feb 2015, 12:38:08 EST by Ms Kate Rowe on behalf of Scholarly Communication and Digitisation Service